Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Kina vs RestorLife Med

Kina
Graded #115

Higher grade

vs+6.599999999999994
RestorLife Med
Graded #261

Lower grade

The verdict

Kina takes it — 69.8/100 to 63.2/100.

Kina grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kina is a menopause-care telehealth platform where GLP-1 is the weight-loss treatment, offered alongside HRT, peptide, and compounded options for menopause symptoms.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKina +34
60
26
Dose & formulationEven
64
64
Clinical oversightRestorLife Med +9
88
97
Labs & monitoringRestorLife Med +2
64
66
FulfillmentRestorLife Med +14
83
97
Contract termsKina +24
61
37
Kina · left barRestorLife Med · right bar

The numbers

MetricKinaRestorLife Med
WeighScore69.8/10063.2/100
GradeCC
Scorecard rank#115#261
Semaglutide$179/mo (starting dose, plus a separate fee, compounded)$299/mo (microdose tier, compounded)
Tirzepatide$179/mo (starting dose, compounded)$399/mo (microdose tier, compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Kina

Graded #115 · C

Strengths

  • Menopause-specialized care — GLP-1 weight treatment alongside HRT, peptide, and compounded options for menopause symptoms
  • Prescribed and monitored by named board-certified physicians at Arora Health & Aesthetics, with dose adjustments included
  • Verifiable LegitScript certification (seal ID 50917967)
  • GLP-1 from $179/month with $0 membership fees, FSA/HSA eligibility, free shipping, and cancel-anytime
  • Compounded semaglutide and tirzepatide, 100% online with a roughly 2-minute intake

Where it loses points

  • Compounded medications are not FDA-approved — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Built for women navigating menopause — less tailored if that is not your situation
  • A separate $50 physician consultation fee applies on top of the medication price
  • The compounding pharmacy partner is not named, and the full list of served states is not published
RestorLife Med

Graded #261 · C

Strengths

  • Verifiable LegitScript certification (seal ID 50400451) plus a named board-certified physician (Dr. Michael Wasef, MD) licensed in all 50 states
  • Full GLP-1 lineup: compounded semaglutide and tirzepatide, plus gentler microdose entry options
  • Generous support — unlimited care-team messaging, monthly check-ins, dosage adjustments, and 1 free blood test per quarter on the GLP-1 protocols
  • Available in all 50 states with free priority shipping, discreet packaging, and roughly 48-hour delivery
  • Transparent multi-month pricing with 50% off your first month; semaglutide protocols are compounded with B12

Where it loses points

  • Compounded medications are not FDA-approved as finished products (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Ongoing pricing is mid-range ($299/mo semaglutide, $399/mo tirzepatide) after the discounted first month
  • The specific partner compounding pharmacy is not named
  • Also markets hormone therapy and anti-aging peptides, not GLP-1 exclusively

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard